The NIH has activated Phase II funding of Sensydia’s Fast-Track STTR grant to support real-world clinical utility studies of the Cardiac Performance System (CPS™). This non-dilutive funding marks a key milestone as the company continues to validate CPS for patients with heart failure and pulmonary hypertension.| Sensydia
Industry veteran brings over 20 years of medical device leadership to guide operations, quality, and infrastructure as Sensydia advances toward FDA submission and commercialization of the Cardiac Performance System (CPS™).| Sensydia
Sensydia has enrolled the first patient in its pivotal clinical study evaluating the Cardiac Performance System (CPS™), a non-invasive solution for hemodynamic assessment. This milestone advances CPS™ toward FDA submission and supports Sensydia’s mission to transform the management of heart failure and other cardiac conditions through faster, safer diagnostics.| Sensydia
Completion of this 50-subject study is a key milestone on the path to delivering the first device for non-invasive and accurate...| Sensydia
NIH STTR Fast-Track grant helps propel Sensydia's non-invasive CPS platform building on recent funding round Los Angeles, CA – June 5,...| Sensydia
Sensydia continues to push the boundaries of AI in heart function assessment Los Angeles, CA – May 9, 2023 – Non-invasive cardiac...| Sensydia
Completion of enrollment for this 225-subject study is a key milestone on the path to delivering the first device for non-invasive and...| Sensydia
External device uses heart sound and AI to deliver rapid cardiac function assessments via tablet to expand hemodynamic evaluation beyond...| Sensydia
Los Angeles – October 1, 2019 – Sensydia Corporation, an innovator in rapid, non-invasive measurement of critical cardiac function,...| Sensydia
The Sensydia Cardiac Performance System (CPS) is the first patient-worn system to provide Ejection Fraction information to clinicians for...| Sensydia
Sensydia Corporation announces that it has complete a Series B financing. The financing was led by Colle Capital and included all Series...| Sensydia
Sensydia Corporation has completed its first round of financing which will be used to develop its patent pending technology to detect critical heart function measures such as Ejection Fraction, Stroke Volume, Cardiac Output, and many heart disease conditions.| Sensydia
The Sensydia Cardiac Performance System (CPS) enables the rapid assessment of critical care and heart failure patients by non-invasively measuring key hemodynamic metrics.| Sensydia
The Sensydia Cardiac Performance System (CPS) is the only hemodynamic monitoring platform that is trained to gold-standard accuracy in a non-invasive system. This clinical breakthrough is enabled by proprietary sensor design, advanced signal processing, and machine learning.| Sensydia
Completion of this 50-subject study is a key milestone on the path to delivering the first device for non-invasive and accurate...| Sensydia